| COVID-19 |
1 |
1 |
| Thromboembolism |
0 |
0.9 |
| Anticoagulation Therapy |
0 |
0.55 |
| Antithrombotics |
0 |
0.95 |
| Hospital |
0 |
0.85 |
| Intensive Care Unit |
0 |
0.8 |
| Heart |
0 |
0.28 |
| Patient Safety |
0 |
0.23 |
| Hemorrhage |
0 |
0.22 |
| New York |
0 |
0.22 |
| Cardiovascular Risk Management |
0 |
0.2 |
| Clinical Research |
0 |
0.17 |
| Deep Venous Thrombosis |
0 |
0.11 |
| Grant |
0 |
0.11 |
| Lung |
0 |
0.11 |
| Thrombosis |
0 |
0.11 |
| Mechanical Ventilation |
0 |
0.07 |
| Adverse Effects |
0 |
0.06 |
| Blood |
0 |
0.06 |
| Cardiovascular disease |
0 |
0.06 |
| Coagulation |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Inpatient Care |
0 |
0.06 |
| Low-Molecular-Weight Heparin |
0 |
0.99 |
| Organ Failure |
0 |
0.06 |
| Surgery |
0 |
0.06 |
| Venous Thromboembolism (VTE) |
0 |
0.06 |
| Pneumonia |
0 |
0.04 |